Mitotane (Lysodren)

Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties.

Mitoxantrone HCl

MIV-247 (MIV247) is a potent, selective, orally active inhibitor of cathepsin S with Ki of 2.1 nM (human cathepsin S).

MIV-711 (MIV711, MV076159) is a potent, selective cathepsin K inhibitor with Ki of 0.98 nM, displays >1300-fold versus the other human cathepsins.

Mizagliflozin (DSP-3235, KGA-3235, GSK-1614235) is a potent, selective, orally active SGLT1 inhibitor with Ki of 27 nM, displays >350-fold selectivity over SGLT2.

Mizoribine(NSC 289637; HE 69; β-Bredinin) is an immunosuppressive agents (IC50=100 uM) that inhibit the proliferation of lymphocytes selectively, via inhibition of IMPDH.

MJN110 (MJN-110) is a potent, selective, and orally active MAGL inhibitor with IC50 of 2.1 nM (2-AG hydrolysis).

MJN-228 is a selective ligand for the lipid-binding protein nucleobindin 1 (NUCB1) with IC50 of 3.3 uM (blocks AEA-DA probe labeling of NUCB1).

MK-0249 is a novel potent, selective histamine H3 inverse agonist for the treatment of cognitive impairment with schizophrenia..

MK-0343 (MRK-409) is a potent, α2/3 subtype selective, partial GABAA receptor agonist, shows greater agonist efficacy at the α3 over α1 subtypes.

MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.

MK-0448 is a potent, specific I(Kur) current/Kv1.5 channel inhibitor with IC50 of 8.6 nM, potently inhibits IKur in human atrial myocytes with IC50 of 10.8 nM.

MK-0674 is a potent, selective, reversible and orally active cathepsin K inhibitor with IC50 of 1 nM.

MK-0731 is a potent, selective kinesin spindle protein (KSP) inhibitor with IC50 of 2.2 nM, cell EC50 of 5.3 nM.

MK1 is a small molecule inducer of megakaryopoiesis (EC90=750 nM) that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes, does not adversely affect erythrocyte differentiation.

MK-1832 is a potent, selective Kv1.5 inhibitor with IC50 of 86 nM, exhibits improved selectivity for IKur over IKs (>3000-fold) compares with MK-0448 (70-fold), also exhibits an improved preclinical pharmacokinetic profile..

MK-1925 is a selective, orally active, brain-penetrant opioid receptor-like 1 (ORL1.

MK-204 is a potent, selective AKR1B10 inhibitor with IC50 of 80 nM, shows high selective (270-fold) over AKR1B1.

MK-2048 is a potent inhibitor of HIV-1 integrase (IN) and IN mutant R263K with IC50 of 2.6 nM and 1.5 nM, respectively.

MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM.

MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM.

MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase with IC50 of 6 nM.

MK-3901 is a potent, selective, orally active P2X3 antagonist with IC50 of 21 nM.

MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM.

MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R currently in clinical development for insomnia.

MK-6169 is a potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 1-33 nM, retains potency against common resistance-associated substitutions in the major genotypes.

MK-6240 is a positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs.

MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM.

MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM.

MK-8141 (ACT-077825) is a novel potent, selective, direct Renin inhibitor for the treatment of cardiovascular disorders..

MK-8245 trifluoroacetate is a potent, selective liver-targeted stearoyl-CoA desaturase (SCD) inhibitor with IC50 of 3, 3 and 1 nM for rat, mouse and human SCD1 enzyme, respectively.

MK-8267 (SCH 2047069) is a potent, orally bioavailable, brain penetrant kinesin spindle protein (KSP) inhibitor with EC50 of 3 nM.

MK-8282 is a potent, selective, oral GPR119 agonist with EC50 of 10 and 58 nM for hGPR119 and mGPR119, respectively.

MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.

MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.

MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK

MK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively.

MK-8591 (Islatravir, MK8591, EFdA) is a nucleoside analog that exhibits remarkable potency against wild-type and drug-resistant HIVs, inhibits HIV-1 reverse transcriptase with multiple mechanisms.

MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.

MK-8825 is a highly potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 17 nM for rat CGRP.

MK-886 is an inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes).

MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM, 18F MK-9470 has been developed for use in human brain imaging..

MKC9989 is a specific small molecule inhibitor of IRE1α Rnase (Kd=0.84 uM) with potency against the splicing of XBP1 mRNA (EC50=0.33 uM)..

MKK7-COV-13 (MKK7 Covalen inhibitor 13) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 10 nM, displays >1,000-fold selectivity over MKK4 (IC50>10 uM).

MKK7-COV-3 (MKK7 Covalen inhibitor 3) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 5 nM, displays >1,000-fold selectivity over MKK4 (IC50=7.81 uM), shows EC50 of 1.3 uM for reduction of p-JNK in ICW assays in Beas2B cell line, wit

MKK7-COV-9 (MKK7 Covalen inhibitor 9) is a potent, selective, covalent MKK7 inhibitor, displays >1,000-fold selectivity over MKK4.

MKT-077 (FJ-776) is a highly water-soluble (>200 mg/ml) rhodacyanine dye that exhibits significant antitumor activity, binds to Hsp70 family member, mortalin (mot-2), and abrogates its interactions with p53.

ML 086 is a potent, specific inhibitor of phosphatase PHOSPHO1 with IC50 of 139 nM, with no activity against TNAP (IC50>100 uM).

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 604086 (ML604086) is a potent, selective CCR8 inhibitor that inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations with IC50 of 1.3 uM and 1.0 uM respectively in cellular assays.

ML 604440 (ML604440, ML-604440) is a potent, specific and cell permeable proteasome β1i (LMP2) subunit inhibitor.

ML 792 is a potent, seletive SUMO-activating enzyme (SAE) inhibitor with IC50 of 3 nM and 11 nM for SAE/SUMO1 and SAE/SUMO2, respectively.

ML RR-S2 CDA ammonium salt is a synthetic cyclic dinucleotide derivative that functions as a highly potent agonist of STING, enhances binding affinity to STING and activates all known human STING alleles.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML090 (ML-090, CCG-44699, Fluoflavin, NSC 179821) is a potent, selecitve inhibitor of NADPH oxidase 1 (NOX1) with IC50 of 90 nM, displays no significant activities against NOX2, 3 and 4 (IC50>10 uM)..

ML092 is a covalent and reversible Cruzain inhibitor, with an IC50 of 10 nM.

ML104 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML115 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML119 (CID1357397.

ML132 (NCGC-00183434, CID-4462093) is a highly potent, selective Caspase 1 inhibitor with IC50 of 0.023 nM, displays >1,000-fold selectivity over a panel of 9 caspases..

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.

ML18 is Bombesin receptor subtype 3 (BRS-3) antagonist (IC50 = 4.8 μM). ML-18 inhibits lung cancer growth.

ML-184 (ML184) is a potent, selective GPR55 agonist with EC50 of 263 nM, >120-fold, 83-fold, and 57-fold selectivity against GPR35, CB1 and CB2.

ML-191 is a potent, selective GPR55 antagonist with 160 nM potency for GPR55 and >100-fold selectivity against GPR35, CB1 and CB2.

ML193 (CID 1261822) is a potent, selective GPR55 antagonist with IC50 of 221 nM, shows >27-, >145- and >145-fold selectivity for GPR55 over CB1, GPR35 and CB2, respectively.

ML197 is a potent, selective small molecule inhibitor of Cdc2-like kinases (CLK) and DYRK with IC50 of 96/40/206 nM for CLK1/CLK4/Dyrk1A, respectively.

ML221 is an antagonist of the apelin (APJ) receptor.

ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM).

ML278 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 6 nM.

ML279 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 17 nM.

ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM. ML281 showed a 550-fold selectivity over AurB and greater than 700-fold selectivity over PKA.

ML-290 is a potent and orally active relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.

ML298 is a potent, selective phospholipase PLD2 inhibitor with IC50 of 355 nM, displays >53-fold selectivity over PLD1 (IC50>20 uM).

ML299 is a potent, CNS penetrant, dual phospholipase PLD1/PLD2 probe with IC50 of 6 nM/20 nM, respectively.

ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.

ML316 is a specific antifungal agent that fungal-selectively inhibits the mitochondrial phosphate carrier Mir1, exhibits potent antifungal activity against the moderatelyazole-resistant C. albicans strain CaCi-2 with MIC of 0.05 ug/ml.

ML350 (CYM 50202) is a highly potent and selective Opioid kappa receptor (OPRK1/KOR) antagonist with IC50 of 9-16 nM.

ML352 (VU-0476201) is a potent, selective choline transporter (CHT) inhibitor with Ki of 92 nM.

ML354 (VU0099704) is a novel potent and selective PAR4 antagonist with IC50 of 140 nM, displays 71-fold selectivity versus PAR-1.

ML358 is a first in class, selective small molecule inhibitor of the SKN-1 pathway with IC50 of 0.24 uM.

ML359 is a small molecule, specific inhibitor of Protein disulfide isomerase (PDI) with IC50 of 250 nM; displays >100-fold selectivity over other thiol isomerases (Erp5, Thioredoxin, Thioredoxin reductase); shows no cytotoxicity in three human cell lines, and some activity in inhibiting platelet aggregation in vitro.

ML368 (SR 9186) is a potent, selective cytochrome P450 enzyme CYP3A4 inhibitor with IC50 of 4 nM (convert testosterone to hydroxytestosterone), displays >2,000-fold selectivity over CYP3A5..

ML372 is a small molecule SMN modulator that increases SMN protein in patient fibroblasts with EC50 of 37 nM; possesses good potency, pharmacokinetics, tolerance, and CNS penetration that are able to increase levels of SMN protein in several model cell lines; increase SMN protein levels in vivo, restore motor function, and prolong survival of SMNΔ7 SMA Mice; improves the righting reflex and extended survival of a severe mouse model of SMA.

ML375 (VU-0483253) is a potent, highly selective M5 NAM with submicromolar potency (human M5 IC50=300 nM, rat M5 IC50=790 nM, M1-M4 IC50> 30 uM), exhibts excellent multispecies PK, high CNS penetration, and enantiospecific inhibition..

ML377 (MLS 0472732) is a small molecule probe that selectively inhibits TAG (Triacylglyceride) accumulation with an IC50 of 1.1 uM, show >45-fold selectivity versus DGAT inhibition and cytotoxicity..

ML378 (CID71710938, JJH-254) is an in vivo active carbamate-based dual inhibitor of lysophospholipase LYPLA1 (APT1) and LYPLA2 (APT2) with IC50 of 122 nM and 245 nM, repectively.

ML379 (CID71576758) is a potent, selective TP53 mutant cancer cells inhibitor with IC50 of 13 nM in sensitive HeLa cells (TP53 mutant).

ML381 (VU0488130) is a highly mAChR subtype selective M5 orthosteric antagonist with IC50/Ki of 450/340 nM for hM5, has no inhibitory activity on hM1-4 (IC50>30 uM).

ML382 is a potent, selective, positive allosteric modulator of Mas-related G protein-coupled receptor X1 (MrgprX1) with EC50 of 190 nM in cell based Ca2+ imaging assay.

ML387 (CID3474778) is a potent, selective NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with IC50 of 19 nM.

ML388 is a potent, selective NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with IC50 of 34 nM.

ML389 is a highly potent, selective vasopressin receptor 1a (V1a-R) antagonist with IC50 of 40 nM.

ML395 is a potent, selective, allosteric phospholipase D2 (PLD2) inhibitor with cellular IC50 of 360 nM, shows >80-fold selectivity over PLD1 (IC50>30 uM).

ML398 (CID72737723) is a potent, selective, highly brain penetrant dopamine 4 (D4) receptor antagonist with IC50/Ki of 130 nM/60 nM.

ML399 (VU0516340) is a potent and cell penetrant menin-MLL inhibitor with IC50 of 90 nM.

ML401 (CID73169083) is a potent, functional antagonist of EBI-2 (Epstein-Barr virus-induced gene 2) with IC50 of 1 nM, displays activity in a chemotaxis assay (IC50=6 nM).

ML404 is a small molecule inhibitor of mtPTP, inhibits mitochondrial swelling with EC50 of 4.9 nM, shows no effect on mitochondrial coupling at >100 uM.

ML406 is a small molecule Mtb bioA (DAPA synthase) enzyme inhibitor (IC50=30 nM) that shows anti-tubercular activity, dispalys >100-fold selectivity over bioD.

ML-60218 (ML60218) is a broad-spectrum, small molecule inhibitor of RNA polymerase (Pol) III with IC50 of 32 and 27 uM for Saccharomyces cerevisiae and human, respectively.

ML-7 Hydrochloride is a selective inhibitor of myosin light chain kinase (MLCK) (Ki = 0.3 μM).

ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.

MLAF50 is the first small-molecule inhibitor of the REV1 UBM2-Ubiquitin interaction, directly binds to REV1 UBM2 with Kd of 37 uM in SPR assays.

MLN 3897 is a potent, specific and orally active antagonist of CCR1 with IC50 of 0.8 nM in competition binding assays, 500-fold selectivity over CCR5.

MLN0905 is a mall-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.

MLN120B is a potent and effective IKKbeta inhibitor.

MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization).

MLS 0038949 is a potent, selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 0.19 uM, shows no activity against IAP and PLAP (IC50>100 uM).

MLS 0263839 is a potent, specific inhibitor of the phosphatase PHOSPHO1 with IC50 of 0.14 uM, shows minimal cross-inhibition of TNAP and no inhibition of ENPP1 activity.

MLS-0322825 is a novel potent low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 3.3 uM.

MLS-0437605 is a specific inhibitor of dual-specificity phosphatase 3 (DUSP3) with IC50 of 3.7 uM, 7-fold selectivity over USP22 and >4-fold selectivity over other 10 PTPs (HePTP, TCPTP, PTP1B, etc.).

MLS1082 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MLS-1547 is a G protein-biased agonist of dopamine D2 receptors (EC50 = 0.37 μM in a calcium mobilization assay).

MLT-747 (MLT747) is a potent, selective, allosteric inhibitor of MALT1 paracaspase with IC50 of 14 nM.

MLT-748 (MLT748) is a potent, selective, allosteric inhibitor of MALT1 paracaspase with IC50 of 5 nM, does not show inhibitory activity against 22 other tested human proteases (IC50>100 uM).

MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.

MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM.

MMAE-(PEG)4-DBCO is made by MMAE conjugated to DBCO-(PEG)4 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

MMBO is a potent, highly selective, brain penetrant, orally active inhibitor of GSK-3 with IC50 of 37 and 53 nM for GSK-3α and GSK-3β, respectively.

MMK7 inhibitor 4a is a potent, sepecific, covalent inhibitor of MMK7, displays >800-fold selectivity over EGFR-WT and EGFR-L858R/T790M.

MMP13-IN-24f is a potent, selective, and orally active MMP-13 inhibitor with IC50/Ki of 0.5/0.19 nM, shows no activity against MMP-1 or TACE (IC50>10 uM).

MMP13-IN-31f is a highly potent, selective, orally bioavailable MMP-13 inhibitor with IC50 of 0.036 nM.

MMP3 inhibitor 1 is a potent and highly selective MMP-3 inhibitor with an IC50 of 1 nM.

MMPI-1154 is a small molecule MMP-2 inhibitor with IC50 of 10/6.6/13/1.8 uM for MMP1/2/9/13, respectively.

MMRi6 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells..

MMRi64 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells.

MMSET-IN-1 is a potent, selective epigenetic oncogene MMSET (aka NSD2 or WHSC1) inhibitor with Ki/IC50 of 1.6/3.3 uM.

MMV390048 is a novel potent Plasmodium PI4K inhibitor with IC50 of 28 nM against intraerythrocytic life cycle stages of P. falciparum (NF54 drug-sensitive strain).

MMV-667492 (MMV 667492, MMV667492) is a novel potent Ezrin inhibitor with Kd of 29.4 nM.

MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression

MN30 (Methyl-3,4-dephostatin, APOBEC3G inhibitor MN30) is a first-in-class, selectve small molecule inhibitor of the single-strand DNA cytosine deaminase APOBEC3G with IC50 of 9.1 uM.

MN58b is a potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.4 uM, >30-fold selectivity over ChoKβ and does not affect MAPKs, PI3Ks, and other enzymes involved in the regulation of phospholipid metabolism.

MNK inhibitor 9 is a potent, selective MAPK-interacting kinase (MNK1 and MNK2) inhibitor with IC50 of 3 nM for both, with no activity aginst CDK1/2 (IC50>25 uM).

MNKI-19 is a potent and dual-specific Mnk inhibitor with Ki of 186 nM and 68 nM for Mnk1 and Mnk2, respectively.

MNKI-85 is a potent and selective Mnk2 inhibitor with Ki of 31 nM, displays no inhibitory activities against Mnk1, CDK2A, CDK9T, and CDK4D.

MNKI-8e (MNK inhibitor 8e) is a potent, selective MNK inhibitor that inhibits Mnk2 with Ki of 0.37 uM, displays >34-fold and 4-fold over CDK2 (Ki>10 uM) and CDK9 (Ki=1.66 uM).

MNK-IN-54 is a potent, orally bioavailable dual MNK1/2 and BCR-ABL1 inhibitor with IC50 of 20/10/200/10 nM for Abl T315I/ wt Abl/MNK1/MNK2, respectively.

Mofezolac is a Highly Selective Cyclooxygenase-1 Inhibitors,Counteracting Inflammatory State both In Vitro and In Vivo Models of Neuroinflammation.

Moguisteine is a novel peripheral non-narcotic antitussive drug.

Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.

Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway.

Molsidomine is an orally active, long acting vasodilating drug, metabolized in the liver to the active metabolite linsidomine, which is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.

Mometasone furoate

Monobenzone (Benoquin)

Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Monomethylauristatin F(MMAF) is an antitubulin agent that inhibit cell division by blocking the polymerization of tubulin; lower cytotoxic activity than MMAE; antibody drug cytotoxin.

Monooctyl succinate is a monoester, which can be used as a surfactants and a potential fragrance releaser.

Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Mosedipimod (EC-18, 1-palmitoyl-2-linoleoyl-3-acetylglycerol) is a synthetic monoacetyldiaglyceride that stimulates T cell production of IL-2, IL-4, IL-12, IFN-γ, and GM-CSF in vitro.

Motolimod (VTX-2337) is a novel TLR8 agonist that activates NK cells and augments ADCC.

Moxonidine

Moxonidine hydrochloride

MP-A08 is a first-in-class, highly selective, ATP competitive sphingosine kinase (SphK) inhibitor (Ki of 6.9/27 uM for SK2/SK1).

MPC1304 is a Ca2+ channel antagonist with potent and long-lasting antihypertensive effects. IC50 & Target: Ca2+ Channel.

MPEP is a potent, highly selective non-competitive antagonist at the mGlu5a receptor subtype (IC50 = 36 nM) while having no agonist or antagonist activities at the mGlu1b receptor at concentrations up to 30 μM.

MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM.

mPGES1-IN-16 is a potent and selective mPGES-1 inhibitor with IC50 of 1 nM.

mPGES1-IN-17d is a potent, selective mPGES-1 inhibitor with enzyme IC50 of 8 nM, A549 cell IC50 of 16.24 nM, human whole blood IC50 of 249.9 nM.

Mps1-IN-3 is a selective and highly potent Mps1 kinase inhibitor with IC50 of 50 nM.

MPTP HCl induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats

MRK-560 is a potent, brain-penetrant and orally bioavailable γ-secretase inhibitor that inhibits proteolytic cleavage of APP over the Notch pathway.

MRK-623 is a potent, α2/α3 subunit functionally selectiviie GABAA receptor agonist..

MRK-696 is a non-selective benzodiazepine receptor partial agonist..

MRK-A is a potent, highly selective, brain penetrant inhibitor of mutant IDH1 with IC50 of 5 nM, displays a 10,000-fold mutant to wildtype selectivity ratio.

MRL-1237 is a potent and selective inhibitor of the replication of Enteroviruses with EC50 of 1-10 uM, targets the nonstructural 2C protein.

MRL20 is a novel synthetic PPARγ ligand and orthosteric agonist with canonical LBP binding affinity of 2 nM.

MRS 1845 is a potent calcium channel protein inhibitor and inhibits capacitative Ca2+ influx in HL-60 cells (IC50 = 1.7 mM).

MRS 2179 is a potent, selective, competitive P2Y1 receptor antagonist with Kb of 100 nM.

MRS 2179 is a potent, selective, competitive P2Y1 receptor antagonist with Kb of 100 nM.

MRS 2481 is a potent, reversible Aβ42 neurotoxicity inhibitor with ID50 of 500 nM, potently blocks the Aβ calcium channel and protects neurons from Aβ toxicity.

MRS 2485 is a potent, irreversible Aβ42 neurotoxicity inhibitor with ID50 of 500 nM, potently blocks the Aβ calcium channel and protects neurons from Aβ toxicity..

MRS1177 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 0.3 nM.

MRS-1706 is a potent and selective adenosine A2B receptor antagonist with Ki of 1.39 nM.

MRS1754 is a selective adenosine A2B receptor antagonist (Ki values are 1.97, 16.8, 403, 503, 570 and 612 nM for hA2B, rA1, hA1, hA2A, hA3 and rA2A receptors respectively).

MRS4458 is a potent, highly specific amtagonist of P2Y14 receptor with IC50 of 169 nM, does not display extensive off-target interactions with biogenic amine receptors..

MRS4478 is a potent, highly specific amtagonist of P2Y14 receptor with IC50 of 269 nM, does not display extensive off-target interactions with biogenic amine receptors..

MRT 199665 is a potent salt-inducible kinases (SIKs) inhibitor with IC50 of 110, 12, 43 nM for SIK1,2,3 respectively.

MRT-83 hydrochloride is a potent Smoothened antagonist that blocks Hedgehog (Hh) signaling in various assays with IC50 of 10 nM.

MRTX1257 (MRTX-1257, MRTX 1257) is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 0.9 nM.

MS012 is a potent and selective inhibitor of G9a-Like Protein (GLP) lysine methyltransferase with IC50 of 7 nM, shows >30-fold selectivity for GLP over G9a and other methyltransferases..

MS-0124 is a potent and selective inhibitor of G9a-like Protein (GLP) lysine methyltransferase with IC50 of 13 nM, shows >30-fold selectivity for GLP over G9a and other methyltransferases..

MS2734 is a bisubstrate Nicotinamide N-methyltransferase (NNMT) with IC50 of 14 uM, Kd of 2.7 uM..

MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 µM).

MS-377 is a potent, selective sigma-1 receptor ligand with Kd of 15.2 nM, showed anti-phencyclidine (PCP), anti-dopaminergic and anti-serotonergic activities.

MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.

MS4077 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=3 nM).

MS4078 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=11 nM).

MS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.

MS7972 is a small molecules that blocks p53 and CREB binding protein (CBP) association.

MsbA inhibitor 1 is a novel small molecule lipopolysaccharide biogenesis inhibitor, inhibits MsbA, an ATP-dependent flippase that translocates LPS across the inner membrane; causes mislocalization of LPS to the cell interior, inhibits Δ5 strain with MIC o

MSC1094308 (MSC 1094308) is a reversible, allosteric inhibitor of the type II AAA ATPase human ubiquitin-directed unfoldase (VCP)/p97 and the type I AAA ATPase VPS4B with IC50 of 7.2 and 0.71 uM, respectively.

MSC2504877 (MSC-2504877) a novel small molecule selective tankyrase inhibitor with IC50 of 0.7/0.8 nM against TNKS1/2, shows 771-fold selectivity for TNKS1 over PARP1 (IC50=0.54 uM).

MSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes.